



Mirna Therapeutics Inc. Appoints Lawrence M. Alleva to Its Board of Directors

Austin, Texas – September 15, 2014 - Mirna Therapeutics, a clinical-stage biotechnology company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the appointment of Lawrence M. Alleva, a former partner with PricewaterhouseCoopers LLP, as an outside director to its Board of Directors.

“We are excited to have Larry join our distinguished group of directors. As a finance professional with more than 30 years of experience in technology industries, his expertise and guidance will be invaluable to Mirna as we continue to build our company along with driving forward the clinical program for MRX34, the first microRNA Replacement Therapy in clinical trials,” said Dr. Paul Lammers, President and Chief Executive Officer of Mirna.

“microRNA Replacement Therapy is an exciting space with great growth potential and I am looking forward to working with Mirna, the leader in the field,” said Mr. Alleva. “I believe my financial management experience with biotechnology companies will further complement the efforts of the board of directors and the company as they grow the business and advance into later clinical trials.”

Prior to his retirement in 2010, Mr. Alleva was with PricewaterhouseCoopers LLP (PwC) for 39 years, 28 of which as a partner with the firm, serving clients primarily in the technology sector. From 2006 until his retirement, Mr. Alleva served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice. He currently serves as director for public companies Tesaro Inc. and Bright Horizons Family Solutions, and previously served on the board of GlobalLogic, Inc. Mr. Alleva received a Bachelor of Science degree in Accounting from Ithaca College and attended Columbia University’s Executive MBA Program.

About Mirna Therapeutics, Inc.

Mirna Therapeutics, Inc. (Mirna) is a clinical-stage biopharmaceutical company developing a broad pipeline of leading microRNA-based oncology therapeutics. Mirna’s lead program, MRX34, a first in class cancer compound, is the first microRNA mimic drug candidate to advance into clinical testing, and is now being studied in a Phase 1 trial in patients with liver cancers and hematological malignancies such as lymphoma and leukemia. Mirna's patent portfolio relating to its proprietary microRNA mimics technology consists of nine issued U.S. patents that include cancer and non-cancer therapeutic use claims related to 15 tumor suppressor microRNAs and more than 100 U.S. and foreign pending patent applications that it either owns or in-licenses from third parties. The company, founded in 2007 and located in Austin, TX, has received significant funding from New Enterprise Associates, Pfizer Venture Investments, Sofinnova Ventures and other private investors. Mirna is also funded by the State of Texas, both

through the State's Emerging Technology Fund and the Cancer Prevention & Research Institute of Texas (CPRIT).

For more information, visit www.mirnarx.com.

Contact:

Kelly France, Ph.D.

kfrance@brewlife.com

415.946.1076